`FAAAS, FACS, FAIC, FRSC, C. Chem.
`
`THINQ Pharma / MVRC Research Mobile: 508-308-3891 What’sApp / 908-262-2428
`7 Jones Court
`
` Mobile 91-987-952-2369 (India) What’sApp
`Hillsborough, NJ 08844
` SKYPE Mukund. Chorghade (Mukund dot Chorghade)
` chorghade@comcast. net
`mukundchorghade@fas.harvard.edu; chorghad@mit.edu
`
`
`
`HIGHLIGHTS
`Thirty-four years of research leadership and project management of multi-million-dollar projects. Creativity in problem
`solving: Creativity in problem solving: Discovery and Development of New Chemical Entities, novel synthetic routes /
`processes and formulations for pharmaceuticals; successful implementation of technology in kilo-labs, pilot and manufacturing
`plants. Expertise in diverse areas of organic synthesis (Discovery Research & Process Development): Carbohydrates, Enzymes,
`Heterocycles, Metalloporphyrins, Molecular Recognition, Natural Products. Research work with eminent chemists: Robert
`Grubbs, Steven Ley, Jean-Marie Lehn, David Dolphin, Yoshito Kishi, Sidney Hecht, Charles Hammer, Jay Groves, Bal Tilak,
`Murzban Wadia, Ashok Vaidya, Colin Suckling, Eric Jacobsen, Ron Raines. Elected fellowships in prestigious academic
`societies (AAAS, ACS, AIC and RSC) Demonstrated skills in management of academic collaborations, global sourcing of new
`chemical entities from custom manufacturers; cGLP/CGMP, technology transfer, regulatory filings and compliance audits.
`Certified Professional in Current Good Laboratory Practices and Good Manufacturing Practices. Experienced executive with
`multi-faceted skills and proven track record of innovation and exceeding organizational goals; service on the Scientific
`Advisory Boards of Corporations and Foundations. Serial Entrepreneur. Visiting Scholar / Scientist at numerous academic
`institutions. Fulbright Specialist Award (2015-2021), Chair, Princeton Section, ACS (2019), Chair RSC-Process
`Chemistry and Technology (2018-2020)
`
`PROFESSIONAL AND BUSINESS EXPERIENCE: President / CSO/ Research Fellow / Research Professor
`
`THINQ PHARMA / CBD SCIENCES GROUP / CHICAGO DISCOVERY SOLUTIONS / MVRC Research 2006-
`THINQ-CRO / D & O PHARMACHEM, PHARMACEUTICALS SCIENCES DIVISION 2003-2006
`CHORGHADE ENTERPRISES / CP CONSULTING
`1995-2003
`Designed, Developed and Directed Chemistry for a variety of therapeutic and chemical applications. Consulted with major
`pharmaceutical and biopharmaceutical companies, on collaborations with industrial, academic and government laboratories
`(domestic and overseas; project management of technology transfer; process re-engineering; supply chain management and
`business development).
`Invented the “Chemosynthetic Livers” as powerful oxidation catalysts for predicting drug metabolites, Valorization
`
`of biomass and environmental remediation
` Used Observational Therapeutics for discovering NCEs through Traditional Medicine
`Collaborated on in and out-licensing of pharmaceutically active moieties.
`
` Discovered and Developed technologies; enhanced capabilities of research laboratories; mentored chemists
`Established strategic partnerships with chemistry-based companies for establishment of strategic partnerships;
`
`conducted cGLP/cGMP training and implementation in academic/industrial laboratories.
` Delivered seminars in numerous academic/industrial laboratories in the U.S.A., Europe, and Asia.
` Visiting Scholar/Fellow at Harvard University, MIT, Princeton, Caltech, Univ. Chicago, Northwestern Northeastern
`Universities, Boston College, Cambridge, University of Strathclyde, ICT, NCL, IICT, ICT, KHRC(India)
`
`2000-2003
`GENZYME CORPORATION, Inc., DRUG DISCOVERY AND DEVELOPMENT, WALTHAM, MA
` Vice President, Pharmaceutical Development Sciences; Member, Corporate Steering Committee
` Directed chemical process and formulations research on pre-clinical and clinical candidates.
` Devised and implemented novel strategies for reduction of drug development cycle times
` Evaluated, selected and qualified vendors, worldwide, for deliveries of drug substance and product
`(cGLP / cGMP) for pre-clinical studies and clinical trials; oversaw and facilitated business processes for
`contract implementation and regulatory compliance by vendors;
` Filed "Investigational New Drug Application" and marketing approval filings with government agencies.
` Provided strategic inputs into alignment of drug discovery and development directions and investments.
`Set and monitored product strategy, made key decisions for project prioritization and resource allocation.
`
`
`1997-1999
`CYTOMED, Inc., Cambridge, MA
` Senior Director, Chemical Sciences Research and Development (1998-1999), Director (1997-98)
` Awarded "Scientist of the Year" for contributions to drug development in 1997.
` Directed chemical process and formulation research; significant lowering of costs.
` Developed novel, cost-efficacious process for drug candidates; seamless technology transfer to plants.
`
`Mylan (IPR2020-00040) Ex. 1003 p. 001
`
`
`
`MUKUND S. CHORGHADE
`
`Page 2
`
` 1991 to 1995
`ABBOTT LABORATORIES, Pharmaceutical Research, North Chicago, IL
`Research Investigator (1991-1992)
` Project Manager (1992-1995)
` Awarded the divisional "Scientist of the Year" award for discovery research in June 1993.
` Designed novel cost-effective synthetic processes for the preparation of multi-kilo quantities of anti-
`convulsants, cholinergic channel activators, and anti-infectives reducing time to market by 25%.
`Launched a new program on the biomimetic synthesis of drug metabolites via metalloporphyrin assisted
`epoxidation and hydroxylation. Elaborate multi-step syntheses were converted to one or two-step catalytic
`reactions thereby saving 75% of development time and 80% of costs.
`
`
`
`COLLEGE DE FRANCE, Paris and Université Louis Pasteur, Strasbourg, France
`Research Scientist / Assistant Director
`Researched, with Professor Jean-Marie Lehn (Nobel Laureate), the phenomena of designed self-assembly and
`molecular recognition. Designed and synthesized diversely substituted pyrimidines, triazines and porphyrins.
`
`1990 to 1991
`
`
`
`1985 to 1990
`DOW CHEMICAL, U.S.A., Midland, MI
`Senior Research Chemist (1985-1989)
`Project Leader (Freeport, TX) (1989-1990)
`Led a team of researchers on metalloporphyrin-assisted epoxidation of terminal alkenes, biomedical applications
`of porphyrins, selective functionalization of carbohydrates.
` Initiated and successfully completed projects related to (ii) bio rational design of environmentally benign
`herbicides (iii) Process Development for pharmaceuticals. Received several performance-based awards.
`
`
`
`HARVARD UNIVERSITY, Cambridge, MA
`Postdoctoral Research Fellow
` Conducted research, under Professor Yoshito Kishi, on the synthesis of complex carbohydrates (potential new
`drugs and non-calorific sweeteners); novel C-C bond forming reactions.
`
`1984 to 1985
`
`
`UNIVERSITY OF VIRGINIA, Charlottesville, VA
`Postdoctoral Research Associate
`Explored, under Professor Sidney Hecht, routes for the synthesis of the pyrimidine moiety of Bleomycin (a drug
`
`in clinical use for treatment of carcinomas, melanomas and Hodgkin's disease); 2' (3') -0- acylated pCpA
`derivatives.
`
`1982 to 1984
`
`GEORGETOWN UNIVERSITY, Washington, D. C.
`Instructor (1981-1982)
`
`1975 to 1982
`Teaching and Research Fellow (1975-1981)
`
`1973 to 1975
`NATIONAL CHEMICAL LABORATORY, Pune, India
`Research Fellow: Under Dr. Bal D. Tilak, investigated the utility of N-aryl azetidines as anti-tumor drugs.
`
`EDUCATION
`
`Ph.D. (Organic Chemistry), 1982, Georgetown University, Washington, D. C.
`Performed research, under Professor Charles Hammer, on the "Synthesis of selected saturated nitrogen
`
`heterocycles; kinetic and mechanistic studies on cyclic chloro amines." Received Sigma XI Graduate Student
`Research Prize, (1982).
`
`M. Sc., 1973, 1st Class (Honors), 1st Rank; B. Sc., 1971, University of Poona, India
`
`MEMBERSHIP OF ACADEMIC/PROFESSIONAL SOCIETIES
`American Chemical Society (Elected Fellow), Chair Princeton Section (2019) Organic Division; Member, Chair,
`Board of Directors Executive Committee and Past Chair, Northeastern and Brazosport Section
`International Union of Pure and Applied Chemistry; Royal Society of Chemistry (Elected Fellow)
`American Association for the Advancement of Science (Elected Fellow); American Institute of Chemists (Elected
`Fellow), Health Sciences Collegium (Elected Fellow)
`New York Academy of Sciences; Sigma XI; World Innovation Foundation (Elected Fellow)
`
`Mylan (IPR2020-00040) Ex. 1003 p. 002
`
`
`
`MUKUND S. CHORGHADE
`
`Page 3
`
`Indian Society of Bio-Organic Chemists, Maharashtra Academy of Sciences (Overseas Fellow), Andhra Pradesh
`and Telengana Academy of Sciences (Foreign Fellow), Indian Society of Chemists and Biologists (Overseas
`Fellow), Fulbright Specialist Award (2015-2021)
`Awards and Distinctions
`“Alkyl Amines Padma Bhushan Prof. B.D. Tilak Chemcon 2002 Distinguished Speaker Award” of the International
`
`Institute of Chemical Engineers.
`"Diamond Jubilee Fellowship", University Department of Chemical Technology, Mumbai, India
`"B. D. Tilak Distinguished Visiting Fellowship", University of Bombay.
`Professor V.M. Kulkarni Fellow under "Professor V. M. Kulkarni Endowment Fund" in Pharmaceutical Science
`and Technology" for the year 2018-2019
`Listed in "American Men and Women of Science", "Who's Who in Science and Engineering".
`
` Government of India National Merit Scholarships at college and university levels
`LANGUAGE PROFICIENCY
`Fluent in English, Hindi and Marathi; excellent working knowledge of German, French and several Indian languages
`
`
`
`
`
`
`
`
`
`DISTINGUISHED SERVICE TO ACADEMIC/PROFESSIONAL SOCIETIES
`American Chemical Society: Henry Hill Awardee (NESACS-October 2014)
`Chair(2019) and Chair-Elect, Member, Board of Directors, Princeton Section 2018
`
`Chair, and Immediate Past Chair, Executive Committee Member, Division of Small Chemicals Businesses 06-
`
`Committee Member, Joint Board Council Committee on Science, Program Chair ComSci, Subcommittee Chair,
`
`Awards and Fellowships for National Medal of Science and Technology
`Committee Member, Joint Board Council Committee on International Activities; Tour Speaker Program;
`Distinguished Consultant Career Consultant Program, Chemical Entrepreneurship Council
`Elected Chair, Brazosport Section, 1990, Chair- Elect Northeastern Section 2006, Chair 2007-2008
`
` Member, Board of Directors and Chairman of the Public Services / Public Affairs Committee, Member
`Publications Committee, Northeastern Section, 1997—2017, Editor, “The Nucleus”, February 2004-July 2004-
` Member, Editorial Advisory Board for "Organic Process Research and Development” and “Chimica Oggi”.
`Reviewer of manuscripts for numerous leading professional journals.
`Chair, US Organizing Committee, ACS-CSIR Symposium, Pune + Hyderabad, 2006-
`
`International Union of Pure and Applied Chemistry:
` Member, US National Committee USNC (2010-7), Titular Member, IUPAC Division VII Committee on Chemistry
`and Human Health (2002-2004 term); Secretary of the Division-2005-, Medicinal Chemistry Section Committee;
`Associate Member, IUPAC Commissions on Biotechnology, New Technologies and Special Topics; Associate
`Member, Committee on Chemical Education. NR USA to Division VII (Chemistry and Human Health),
`Project Leader of “New Projects Teams” on Naturaceuticals, Glossaries of Terms used in Process Chemistry” and
`Training in Medicinal Chemistry in South East Asia.
` Chair, Scientific Program Committee, 20th IUPAC Conference on the Chemistry of Natural Products, Chicago,
`September 1996.
`Other Organizations:
`Chair and US Representative, RSC-Process Chemistry and Technology Committee Group (2018-2020) Member-at-
`
`Large, Executive Committee of the Royal Society of Chemistry, US chapter
` Co-chair, Process Development Committee, Massachusetts Biotechnology Council.
` Director and Member, Committees on Advanced Professional Thinking, International Activities and Technology,
`American Institute of Chemists.
` Consultant, Transfer of Knowledge through Expatriate Nationals (TOKTEN) and United Nations Development
` Visiting scholar and adjunct faculty member, Caltech (2006-2007), Cambridge University (2006-2007), Harvard
`University (2005-2006, 2009-), Massachusetts Institute of Technology (2007-), Massachusetts College of Pharmacy
`(2005-2008), Tufts University, Wellesley College, University of Chicago, Northwestern University, University of
`British Columbia, University of Houston, Saginaw Valley College, Michigan, Shishubharati (2001-) Institute of
`Chemical Technology, Mumbai (2013-), Overseas Director, SP Mandali (2013-)
` Course Director and Faculty, CMC Courses, Center for Professional Advancement. and cGLP / cGMP courses, The
`Center for Professional Innovation & Education
` Actively involved with TiE, India Cultural Coordination Committee, Washington, D. C., and leadership roles in
`several community groups.
`SCIENTIFIC ADVISORY BOARDS
`Envision Biotech, Civenti Chem, Raleigh, North Carolina, ROW2, Parsippany, New Jersey; MA, International
`
`Brain Research Foundation, New York, New Jersey Stem Cell Research Foundation
`
`Mylan (IPR2020-00040) Ex. 1003 p. 003
`
`
`
`MUKUND S. CHORGHADE
`
`Page 4
`
` MUKUND S. CHORGHADE, Ph. D.
`
`2019
`
`2)
`
`8)
`
`Publications:
`1) Thomas G. Heckler, Li-Ho Chang, Yoshiyuki Zama, Takehiko Naka, Mukund S. Chorghade and Sidney M. Hecht*, "T4
`RNA Ligase Mediated Preparation of Novel Chemically Misacylated tRNA phe's", Biochemistry, 1984, 23 (7), 1468.
`James R. Roesser, Mukund S. Chorghade and Sidney M. Hecht*, "Ribosome Catalyzed Formation of an Abnormal Peptide
`Analogue", Biochemistry, 1986, 25 (21), 6361.
`3) Yoshiaki Aoyagi, Mukund S. Chorghade, Abeysinghe A. Padmapriya, Hosbett Suguna and Sidney M. Hecht*, "Synthesis
`of Pyrimidoblamic Acid and Epipyrimidoblamic Acid", J. Org. Chem., 1990, 55 (26), 6291.
`4) Mukund S. Chorghade, David E. Basque, Dennis G. Lay* and Paul E. Cranley, "MDI Prepolymers Rival TDIs in PU
`Sealant Formulations", Adhesives Age, 1992, 32.
`5) M. Chorghade, D. G. Lay* and P. Cranley, "2, 4’ MDI based Prepolymers: A Viable Alternative to TDI Prepolymers in
`Polyurethane Sealants", Polyurethanes World Congr. Proc., SPI / ISOPA, 1991, 319
`6) Knud E. Andersen, Mikael Begtrup, Mukund S. Chorghade, Jesper Lau, Elaine C. Lee, Behrend F. Lundt, Hans Petersen,
`Per O. Sorensen* and Henning Thogersen, "The Synthesis of Novel GABA Uptake Inhibitors, Part 2. Synthesis of 5-
`Hydroxytiagabine, a Human Metabolite of the GABA Reuptake Inhibitor Tiagabine", Tetrahedron, 1994, 50 (29), 8699
`Erratum cited in Tetrahedron, 1996, 52 (10), 3375
`7) Mukund S. Chorghade*, Peter Ellegaard, Elaine C. Lee, Hans Petersen and Per Olaf Sorensen, "Synthesis of Desmethyl
`Tiagabine", Heterocycles (special issue honoring Alan Katritzky), 1994, 37 (2), 783.
`Jan V. Andersen, Mukund S. Chorghade*, Derek A. Dezaro, David H. Dolphin, David R. Hill, Elaine C. Lee, Kristian
`T.Hansen and Richard J. Pariza, "Metalloporphyrins as Chemical Mimics of Cytochrome P-450 Systems", Bioorganic and
`Medicinal Chemistry Letters, 1994, 4 (24), 2867.
`9) Gary Callen, Mukund S. Chorghade*, Elaine C. Lee, Peter G. Nielsen, Hans Petersen and Abu Rustum, "Identification and
`Synthesis of Major Oxidative Degradation Products of Tiagabine", Heterocycles (special issue honoring Arnold Brossi),
`1994, 39 (1), 293.
`10) Joseph E. Celebuski, Mukund S. Chorghade* and Elaine. C. Lee, "Chemical Modification of Erythromycin: Novel
`Reaction Observed by Treatment with Metalloporphyrins", Tetrahedron Lett., 1994, 35 (23), 3837. Corrigendum
`published in Tetrahedron Lett., 1995, 36 (52), 9414.
`11) Mukund S. Chorghade* and Elaine. C. Lee, "Progress of an Anti-Convulsant Drug from Discovery to Manufacture", J.
`Indian Inst. Sci., 1994, 74, 231.
`12) Mukund S. Chorghade* and Csaba Cseke, "Biorational Design of Herbicides: Synthesis of Inhibitors of the PFP Enzyme",
`Pure and Appl. Chem., 1994, 66 (10/11), 2211.
`13) Mukund S. Chorghade*, Csaba T. Cseke and Paul S. Liu, "The Utility of 2,5-Dideoxy-2, 5-imino-D-mannitol as a PFP
`Enzyme Inhibitor", Tetrahedron Asymmetry, 1994, 5 (11), 2251.
`14) Mukund S. Chorghade* and Csaba T. Cseke, "Biorational Design of Herbicides: Synthesis of Inhibitors of the PFP
`Enzyme", Heterocycles (special issue honoring Rolf Huisgen), 1995, 40 (1), 213.
`15) V. Rama Rao*, Mukund K. Gurjar, Shashwati Pal, Richard J. Pariza and Mukund S. Chorghade, "Synthesis of a Novel C2-
`Symmetrical (2S, 5S)-2,5-Bis-[(1,1-dimethyl-ethoxy) carbonylamino]-1,6-diphenylhex-3-ene: Applications
`in
`the
`Synthesis of Potential HIV Protease Inhibitors", Tetrahedron Lett., 1995, 36 (14), 2505.
`16) M. S. Chorghade*, H. Petersen, E. C. Lee and S. Bain, "Efficient Synthesis of Regioisomers of Tiagabine", Pure and Appl.
`Chem.,, 1996, 68 (3), 761.
`17) Mukund S. Chorghade*, David H. Dolphin*, David R. Hill, Fumio Hino, Elaine C. Lee, Li-Ying Zhang and Richard J.
`Pariza, "Metalloporphyrins as Chemical Mimics of Cytochrome P-450 Systems", Pure and Appl. Chem., 1996, 68 (3), 753.
`18) David R. Hill, Joseph E. Celebuski, Richard J. Pariza, Mukund S. Chorghade*, Milton Levenberg, Thomas Pagano,
`George Cleary, Paul West and David Whittern, "Novel Macrolides via meso-Tetraarylmetalloporphyrin Assisted
`Oxidations", Tetrahedron Lett., 1996, 37 (6), 787.
`19) M. S. Chorghade*, D. H. Dolphin*, D. Dupre, D. R. Hill, E. C. Lee and T. P. Wijesekara, "Improved Protocols for the
`Synthesis and Halogenation of Sterically Hindered Metalloporphyrins", Synthesis, 1996, 1320.
`20) M. K. Gurjar*, S. Pal, A. V. Rama Rao, R. J. Pariza and M. S. Chorghade, "Synthesis of Novel C-2-symmetric and Pseudo
`C2-symmetric Based Diols, Epoxides and Dideoxy Derivatives of HIV Protease Inhibitors", Tetrahedron, 1997, 53 (13),
`4769.
`21) B. Venkateswara Rao*, B. V. Sarma, S. V. Ravindranadh, M. K. Gurjar and M. S. Chorghade, "Selective Hydrolysis of
`Isopropylidene Group of Sugar Derivatives with Oxone in Aqueous Methanol", Carbohydrate Lett., 1997, 2, 377.
`22) M. K. Gurjar*, K. Sadalapure, S. Adhikari, B. V. N. B. S. Sarma and M. S. Chorghade, "Kinetic Resolution of Aryl
`Glycidyl Ethers: A Practical Synthesis of Optically Pure beta -blocker-S-Metoprolol", Heterocycles, 1998, 48 (7), 1471.
`23) Mahendra N. Deshpande*, Jufang Barkalow, David Brown, Michael H. Cain, Gary Callen, Mukund Chorghade, Ashok
`Gupta, Roger Koops, Richard Pariza, Ketan Patel, Subhash R. Patel, and Pulla Reddy Singam, "A Scalable Process for a
`Novel Antidepressant (ABT-200)", Org. Process Res. Dev., 1998, 2 (6), 351
`24) Mukund K. Gurjar*, L. Murali Krishna, Bugga V. N. B. S. Sarma and Mukund S. Chorghade, "A Practical Synthesis of
`(R)-(-)-Phenylephrine Hydrochloride", Org. Process Res. Dev., 1998, 2 (6), 422.
`
`Mylan (IPR2020-00040) Ex. 1003 p. 004
`
`
`
`MUKUND S. CHORGHADE
`
`Page 5
`
`25) Mukund S. Chorghade*(Editor) and Elaine C. Lee (Associate Editor), Pure and Appl. Chem., 1998, 70 (2), Proceedings of
`the XXth IUPAC Symposium on the Chemistry of Natural Products, Chicago, September 1996, preface page vi
`26) Mukund S. Chorghade*, Liang Guo, Robert M. Moriarty, Raju Penmasta, Munagala S. Rao, Rajesh K. Singhal, Zhengzhe
`Song, Sudersan M. Tuladhar, Sanmin Yang, T. V. Radhakrishnan and D. G. Sathe, "Industrial Synthesis of N-acetyl-5-
`methoxytryptamine (Melatonin)", The Chemist, 1998, 75(4), 27
`27) Mukund S. Chorghade*, Karen A. Jauregui, Sunil V. Mhaskar, Colin Scott and C. Grace Yeh, "Discovery and
`Development of an Anti-Inflammatory Medication", The Chemist, 1998, 75 (5), 32.
`28) Mukund S. Chorghade* and Veena M. Chorghade, "Promise and Potential of the Pharmaceutical Sector in India:
`Opportunities and Challenges for Strategic Collaboration", Chimica Oggi, 1998, 10 (16), 33.
`29) Mukund S. Chorghade*, "Metalloporphyrins as Synthetic Livers", published in "Drug Metabolism: Databases and High
`Throughput Testing During Drug Design and Development", International Union of Pure and Applied Chemistry: DMDB
`Working Party, Ed. Paul W. Erhardt, Blackwell (1999), pp.152-162.
`30) S. Lahiri, C. Ramarao, A. V. Rama Rao, B.V. Rao*, and M. S. Chorghade, "A Facile Synthesis of 5, 6-dimethoxy-1-
`tetralone", Org. Process Res.Dev., 1999, 3 (1), 71.
`31) Xiong Cai, Mukund S. Chorghade*, Aberra Fura, Gurmit S. Grewal, Karen A. Jauregui, Ralph T. Scannell, Michelle
`Young, C. Grace Yeh, Liang Guo, Robert M. Moriarty, Raju Penmasta, Munagala S. Rao, Rajesh K. Singhal, James P.
`Staszewski, Sudersan M. Tuladhar and Sanmin Yang, "Kilogram Scale Synthesis of a Potent 5-LO Inhibitor", Org. Process
`Res. Dev., 1999, 3 (1), 73.
`32) Mukund S. Chorghade*, Liang Guo, Robert M. Moriarty, Raju Penmasta, Munagala S. Rao, Rajesh K. Singhal, Zhengzhe
`Song, Sudersan M. Tuladhar, Sanmin Yang, T. V. Radhakrishnan and D. G. Sathe, "Industrial Synthesis of N-acetyl-5-
`methoxytryptamine (Melatonin)", Submitted to Organic Process Research and Development. Now to be resubmitted
`33) M. S. Chorghade*, M. K. Gurjar, S. Adhikari, K. Sadalapure, S. V. S. Lalitha, A. M. S. Murugaiah and P. Radha Krishna,
`"Synthesis of (2S, 5S)-trans-5-(4-fluorophenoxymethyl)-2-(1-N-hydroxyureidyl-3-butyn-4-yl)-tetrahydrofuran-CMI-977",
`Pure and Appl. Chem., 1999, (6), 1071-74.
`34) Mukund S. Chorghade*, "Professor Sir Derek Harold Richard Barton-In Memoriam", Pure and Appl. Chem., 1999, (6),
`1075-77; reprinted in The Nucleus, 1999, LXXVII, (10), 20
`35) M. S. Chorghade*. K. Sadalapure, S. Adhikari, S. V. S. Lalitha, A. M. S. Murugiah, P. Radha Krishna, B. Sridhar Reddy
`and M. K. Gurjar*, "Synthesis of (2S, 5S)-trans-5-(4-fluorophenoxymethyl)-2-(1-N-hydroxyureidyl-3-butyn-4-yl)-
`tetrahydrofuran (CMI-977): A Potent 5-Lipoxygenase Inhibitor", Carbohydrate Lett, 2000, 3(6), 405-410.
`36) Mukund K. Gurjar*, Andappan M. S. Murugaiah, Joseph Cherian and Mukund S. Chorghade, "Synthesis of (4R)-4-
`Benzyloxycyclopent-2-en-1-one and 1,9-Dioxabicyclo (4.3.0) non-3-enes by Ring Closing Metathesis of Carbohydrate
`Precursors", Carbohydrate Lett, 2000, 3 (5), 343-348.
`37) Darren J. Dixon, Steven V. Ley*, Dominic J. Reynolds and Mukund S. Chorghade, “A Short and Efficient Stereoselective
`Synthesis of the Potent, 5-Lipoxygenase Inhibitor CMI-977", Synthetic Communications, 2000, 30 (11), 1955
`38) M. S. Chorghade*, M. K. Gurjar*, S. Adhikari, K. Sadalapure, S. V. S. Lalitha, A. M. S. Murugaiah and P. Radha Krishna,
`"An Efficient Stereocontrolled Synthesis of Anti-asthmatic Compound CMI-977", Tetrahedron Lett, Submitted. Now to be
`resubmitted
`39) Mukund S. Chorghade, Elaine C. Lee, Gary Callen, Jonathan Pease, Hormuz Mazdiasni, Robert Rickert, Richard J. Pariza,
`Steve J. Wittenberger, Dieter O. Beer, Thomas K. J.Esch, Thomas C. Herzig, Christian C. Witzig, A. V. Rama Rao, B.
`Venkateswara Rao, V. Satish Kumar and M. Nagarajan, "Efficient Syntheses of (S)-Methyl-2-Pyrrolidinyl)-Isoxazole
`Hydrochloride: A Novel Cholinergic Cognition Enhancer", Organic Process Research and Development, Submitted . Now
`to be resubmitted
`40) Mukund K. Gurjar*, L. Murali Krishna, B. Sridhar Reddy, and Mukund S. Chorghade*, "A Versatile Approach to an Anti-
`Asthmatic Compound LDP-977 and its Six Membered Analogue", 2000, Synthesis, 557.
`41) Mukund S. Chorghade*, Edwin D. Becker, John W. Jost, Edwin P. Przybylowicz, and Cynthia Friend, “IUPAC:
`A Glorious Past, Productive Present and Bright Future”, The Nucleus, 2000, LXXXVIII, No. 19, 10; Part II: The
`Nucleus, LXXXIX, 1, 16.
`42) Ramesh A. Joshi, Mukund K. Gurjar*, Narendra K. Tripathy and Mukund S. Chorghade*, “A New and Improved
`Process for Celiprolol Hydrochloride”, Organic Process Research and Development, 2001, 5, (2), 176.
`43) G.V. M. Sharma*, K. Raman Kumar, Punna Sreenivas, Palakodety Radha Krishna and Mukund S. Chorghade, “FeCl3
`Mediated Synthesis of 2-substituted and 2,5-disubstituted Tetrahydrofurans from 1,4-Diols”, Tetrahedron Asymm., 2002,
`13, 687-690
`44) Mukund S. Chorghade*, Veena M. Chorghade and Mukund K. Gurjar, "Promise and Potential of the Pharmaceutical
`Sector in India: Opportunities and Challenges for Strategic Collaboration", Chimica Oggi, 2001, Outsourcing
`Compendium, 45-51
`45) Monge, M. Chorghade, P.W. Erhardt, C.R. Ganellin, N.Koga, P. Lindberg, T.J. Perun, J.G. Topliss, B.K. Trivedi & C.G.
`Wermuth, “Medicinal Chemistry in the Development of Societies. Biodiversity and Natural Products”, Eur. J. Med.
`Chem., 2000, 35 (12), 1121-1125; Acta Farmacéutica Bonaerense, 2000, 9 (4), 309-313; Boletin de la Sociedad Quimica
`del Peru, 2000, LXVI, 210-217; Ingeniera y Ciencia Quimica, 2000, 19, 2; Quim Nova (Brazil), 2001, 24 (1), 153-155;
`Chemistry International, 2001, 23 (2), 39-42; Anales de la Real Academia De Farmacia (Spain), 2001, 67, 5-14; Anales de
`la Real Sociedad Espanola de Quimica (Spain), 2001, 1, 26-31.
`
`Mylan (IPR2020-00040) Ex. 1003 p. 005
`
`
`
`MUKUND S. CHORGHADE
`
`Page 6
`
`46) Mukund S. Chorghade*, Veena M. Chorghade and Mukund K. Gurjar, “Pharmaceutical Industry in India”, The
`Nucleus, 2001, LXXX, No. 3, 12
`47) Darren J. Dixon, Steven V. Ley*, Dominic J. Reynolds and Mukund S. Chorghade, “A Short and Efficient Stereoselective
`Synthesis of the Potent, 5-Lipoxygenase Inhibitor CMI-977", Indian Journal of Chemistry, 2001, 39, 1043
`48) Mukund S. Chorghade*, Mukund K. Gurjar* and Arindam Talukdar, “Fascinating Excursions into Chiral Chemistry: An
`Insider’s Perspective”, Chimica Oggi, 2002, October 2002, 20-26
`49) Mukund K. Gurjar*, A. M. S. Murugaiah, Dandepally Srinivas Reddy and Mukund S. Chorghade, “A New Route to
`Prepare 6-Chloro-5- (2-chloroethyl)-oxindole”, Organic Process Research and Development, 2003, 7, (3), 309
`50) Mukund S. Chorghade*, Steven M. Allin, Darshan G. Vaidya, Michael I. Page, Alexandra M. Z. Slawin, Tim Smith,
`Gerhard Steinbauer, Michael Hartmann, Sylvia Krich, Alexander Rieder, Michael Simetzberger, Toni Chancellor, Aharon
`Cohen, Rayomand H. Gimi, Sunil M. Mhaskar, Eugene Zhorov and Mukund K. Gurjar, “Attempted Template
`Manipulation of the Thiazolo [2, 3-a] isoindolin-1-one and Other Ring Systems for Synthesis of Amino Acids”,
`Tetrahedron, Submitted Now to be resubmitted
`51) Michael Hartmann*, Helmut Koller, Sylvia Krich, Roland Obermüller, Alexander Rieder, Michael Simetzberger, Thomas
`Zich, Gerhard Steinbauer, Toni Chancellor, Mukund S. Chorghade*, Aharon Cohen, Rayomand H. Gimi, Sunil M.
`Mhaskar, Ron Swearingen, Kristine Riley, Eugene Zhorov, Mukund K. Gurjar, Joseph Cherian, Ashok Kamerkar, A. K. S.
`Bhujanga Rao and Karl Reuter, “Development of a Cost-Efficient Process for GT 56-252, A Novel, Orally Available Iron
`Chelator”, Organic Process Research and Development, Submitted. Now to be resubmitted
`52) Mukund K. Gurjar*, Somu V. Ravindranadh, Kuppuswamy Sankar, Sukhen Karmakar, Joseph Cherian, and Mukund S.
`Chorghade, “A New Protocol to Install Geminal Diallyl Functionality via Radical Mediated Ring Opening Reaction of
`Cyclopropyl methyl halide/xanthate with allyl tri-n-butyltin”, Organic and Biomolecular Chemistry, 2003, 14 (10), 1363-
`1370.
`53) Mukund K. Gurjar*, A. M. S. Murugaiah, P. Radhakrishna, C. V. Ramana and Mukund S. Chorghade*, “A Novel and
`Simple Asymmetric Synthesis of CMI-977 (LDP-977): A potent Anti-Asthmatic Drug Lead”, Tetrahedron Asymmetry,
`2003, 14 (10), 1363-1370
`54) Mukund S. Chorghade*, “Pharma Outsourcing”, Chimica Oggi, Outsourcing Compendium, 2003, 2
`55) Mukund S. Chorghade*, Mukund K. Gurjar and Sanjeev Katti, “Chiral Debate on Proprietary Asymmetric Catalysis
`Technology“, Chimica Oggi, 2003, 20, November / December, 10
`56) Mukund S. Chorghade*, “How to Function in Cross-Functional Teams”, The Nucleus, 2003, LXXXII, (8), 10
`57) Mukund S. Chorghade*, Mukund K. Gurjar and C. V. Ramana, “Fascinating Excursions into Chiral Chemistry: An
`Insider’s Perspective”, Chimica Oggi, 2003, September 2003, 13-23.
`58) Mukund S. Chorghade*, Veena M. Chorghade, Mukund K. Gurjar, Ashok V. Kamerkar, and Harry Zafran, “Collaboration
`with Chinese Companies for Rapid Drug Development”, Chimica Oggi, Fine Chemicals Custom Manufacturing Directory
`2003, 30-34
`59) Mukund S. Chorghade*, Veena M. Chorghade, Mukund K. Gurjar, Ashok V. Kamerkar, and Harry Zafran, “Collaboration
`with Indian Companies for Accelerating the Drug Development Process”, Chimica Oggi, Fine Chemicals Custom
`Manufacturing Directory, 2003, 74-78
`60) Bhushan Patwardhan*, Ashok D.B. Vaidya and Mukund Chorghade, “Ayurveda and Natural Product Drug Discovery”,
`Current Science, 2004, 89, 6, 789
`61) Anand Apte, Mukund S. Chorghade*, Veena M. Chorghade, Janos Fischer, Giovanni Gaviraghi, Mukund K. Gurjar, Susan
`Dana Jones, Sanjeev Katti, Carlos Rosas, John R. J. Surtees, “Glossary of terms used in process chemistry/manufacturing
`of active pharmaceutical ingredients”, Pure and Applied Chemistry, In Press
`
`62) Eli Breuer, Gershon Golomb, János Fischer and Mukund S. Chorghade, “Glossary of terms used in pharmaceutics”, Pure
`and Applied Chemistry, In Press
`
`63) Mukund Chorghade*, Bhushan Patwardhan, Ashok D.B. Vaidya, Mukund K. Gurjar, Mrs. Swati P. Joshi, Dr. Sajid
`Husain, Dr. Sheikh Imam, G. Sriram, Sohail Hussian, Dr. S. J. Hussain, Wenhan Lin, & Lihe Zhang, “Chemical,
`pharmacological aspects of natural products with medicinal and nutritive value”, Pure and Applied Chemistry, In Press
`64) Mukund Chorghade*, Veena Chorghade, Mukund K. Gurjar, “Research and Training in Medicinal Chemistry in India,
`Pakistan and Sri Lanka: A comprehensive survey to ascertain status and sophistication of faculties and doctorate programs:
`Recommendations for a standardized curriculum”, Pure and Applied Chemistry, In Press
`65) Mukund S. Chorghade*, Elaine Diggs, Truman Light, Arlene Light, Bruce Millar, Dorothy Rodman, Jura Viesulas, “An
`Employment Guide for ACS Members”, The Nucleus, 2004, LXXXII, (6), 10
`66) Mukund S. Chorghade*, Mukund K. Gurjar* and C.V. Ramana, “Building Business Based on Pharma Industry’s Interests:
`Integration of Basic and Applied Research”, SP2, November 2004, 3, 34
`67) Mukund S. Chorghade*, Veena M. Chorghade, Mukund K. Gurjar, C. V. Ramana, Ashok V. Kamerkar, Harry Zafran,
`and Raghunath A. Mashelkar, “Building Business Based on Pharma Industry’s Interests: Integration of Basic and Applied
`Research”, Chimica Oggi, Outsourcing Today, Supplement, 16, 2004
`68) Mukund K. Gurjar*, B. Venkateswara Rao, L. Murali Krishna, Steven V. Ley and Mukund S. Chorghade*,
`”Stereoselective Synthesis of (2S, 7S)-7-(4-Phenoxy methyl)-2-(1-N-hydroxyureidyl-3-butyn-4yl) Oxepane; a seven –
`
`Mylan (IPR2020-00040) Ex. 1003 p. 006
`
`
`
`MUKUND S. CHORGHADE
`
`Page 7
`
`membered ring compound with promise as an anti-asthmatic drug candidate”, Tetrahedron Asymmetry, 2005, 16 (6), 935-
`939
`69) G V M Sharma*, Sreenivas Punna, T Rajendra Prasad, Palakodety Radha Krishna, Steven V. Ley and Mukund S
`Chorghade*, “Stereoselective Syntheses of Pharmaceutically Relevant Chiral Tetrahydrofurans From (R) - and (S)-
`Glyceraldehyde Derivatives”, Tetrahedron Asymmetry, 2005, 16 (6), 1113-1123
`70) G V M Sharma,* Sreenivas Punna, Palakodety Radha Krishna, Steven V. Ley and Mukund S Chorghade*, “Flexible and
`Linear Stereoselective Synthesis of Chiral Tetrahydrofurans with Potent 5-LO Inhibitory Activity”, Tetrahedron
`Asymmetry, 2005, 16 (6), 1125-1133
`71) G V M Sharma*, Sreenivas Punna, Lanka Hymavathi, N Yella Reddy, Palakodety Radha Krishna, Steven V. Ley and
`Mukund S Chorghade*, “Mannose Diacetonide” as a Template for Stereoselective Synthesis of (2R, 3S, 4S,5R)-trans-3,4-
`Dihydroxy-5-(4-fluorophenoxymethyl)-2-(1-N-hydroxyuriedyl-3-butyn-4-yl) tetrahydrofuran and (2R, 3S, 4S, 5R)-trans-
`5-ethynyl-2-(4-fluorophenoxymethyl)-3, 4-O-isopropylidene tetrahydrofuran”, Tetrahedron Asymmetry, 2005, 16 (6),
`1135-1140
`72)Bhushan Patwardhan, Dnyaneshwar Warude, Chorghade Mukund, P. Pushpangadan, Narendra Bhatt,
`“Ayurveda and
`Traditional Chinese Medicine: Global Markets and Science”, submitted for publication to Therapy
`73) Mukund S. Chorghade*, Veena M. Chorghade, Mukund K. Gurjar, C. V. Ramana, Ashok V. Kamerkar, Harry Zafran,
`and Raghunath A. Mashelkar, “India: A Premier Destination for Outsourcing”, Speciality Chemicals Magazine, Jan / Feb
`2005, 42-43
`74) C.V. Ramana*, N. Raghupathi, Mukund K. Gurjar and Mukund S. Chorghade, “A carbohydrate based approach for the
`total synthesis of strictifolione, Tetrahedron Lett., 2005, 46, 4073-4075
`75) Mukund K. Gurj